← Eichor
Study identifier: NCT05674825 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Condition: Cancer  ·  Sponsor: Medical College of Wisconsin

PhasePhase 1/Phase 2
Planned participants400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, the investigators now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, the investigators are testing a strategy of molecular matching that may apply across different cancers.

This description comes directly from the study's public registry record.

Talk to the study team

Medical College of Wisconsin Cancer Center Clinical Trials Office  ·  866-680-0505  ·  cccto@mcw.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Froedtert Hospital & the Medical College of WisconsinMilwaukee, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05674825